Effects of kinin B1 and B2 receptor antagonists on overactive urinary bladder syndrome induced by spinal cord injury in rats

British Journal of Pharmacology

Volumn 167, Issue 8, 2012, Pages 1737-1752

  Forner, Stefânia ^a   Andrade, Edinéia L ^a   Martini, Alessandra C ^a   Bento, Allisson F ^a   Medeiros, Rodrigo ^a,b   Koepp, Janice ^a   Calixto, João B ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

B1 and B2 kinin receptors; overactive bladder; pro inflammatory interleukins; spinal cord injury

Indexed keywords

ICATIBANT; KININ B1 RECEPTOR ANTAGONIST; KININ B2 RECEPTOR ANTAGONIST; KININ DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CYSTOMETRY; DETRUSOR MUSCLE; DRUG MECHANISM; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFLAMMATION; MALE; NONHUMAN; OVERACTIVE BLADDER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPINAL CORD; SPINAL CORD INJURY; SPINAL GANGLION; UROTHELIUM;

ANIMALS; GANGLIA, SPINAL; MALE; MUSCLE CONTRACTION; RATS; RATS, WISTAR; RECEPTOR, BRADYKININ B1; RECEPTOR, BRADYKININ B2; SPINAL CORD INJURIES; URINARY BLADDER; URINARY BLADDER, OVERACTIVE;

EID: 84870539841     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02127.x     Document Type: Article

References (72)

1. Ahluwalia A, Maggi CA, Santicioli P, Lecci A, Giuliani S, (1994). Characterization of the capsaicin-sensitive component of cyclophosphamide- induced inflammation in the rat urinary bladder. Br J Pharmacol 111: 1017-1022.
2. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edition (2011). Br J Pharmacol 164 (Suppl. 1): S1-S324.
3. Andrade EL, Forner S, Bento AF, Leite DFP, Dias MA, Leal PC, et al,. (2011). TRPA1 Receptor modulation attenuates bladder overactivity induced by spinal cord injury. Am J Physiol Renal Physiol 300: F1223-F1234.
4. Basso DM, Beattie MS, Bresnahan JC, (1995). A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma 12: 1-21.
5. 1 receptor expression in urinary bladder of cyclophosphamide-treated rats. Br J Pharmacol 128: 213-219.
6. Bento AF, Marcon R, Dutra RC, Claudino RF, Cola M, Leite DF, et al,. (2011). Caryophyllene inhibits dextran sulfate sodium-induced colitis in mice through CB2 receptor activation and PPARÎ pathway. Am J Pathol 178: 1153-1166.
7. Bradford MM, (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
8. Brading AF, (1997). A myogenic basis for the overactive urinary bladder. Urology 50: 57-73.
9. Buckner SA, Milicic I, Daza AV, Coghlan MJ, Gopalakrishnan M, (2002). Spontaneous phasic activity of the pig urinary bladder smooth muscle: characteristics and sensitivity to potassium channel modulators. Br J Pharmacol 135: 639-648.
10. Calixto JB, Cabrini DA, Ferreira J, Campos MM, (2000). Kinins in pain and inflammation. Pain 87: 1-5.
11. 1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes. Br J Pharmacol 143: 803-818.
12. Campos MM, Souza GEP, Calixto JB, (1998). Modulation of kinin B1 but not B2 receptors-mediated rat paw edema by IL-1[beta] and TNF[alpha]. Peptides 19: 1269-1276.
13. Campos MM, Souza GEP, Calixto JB, (1999). In vivo B1 kinin-receptor upregulation. Evidence for involvement of protein kinases and nuclear factor kB pathways. Br J Pharmacol 127: 1851-1859.
14. Chopra B, Barrick SR, Meyers S, Becker JM, Zeidel ML, Ford APDW, et al,. (2005). Expression and function of bradykinin B1 and B2 receptors in normal and inflamed rat urinary bladder urothelium. J Physiol 562: 859-871.
15. Couture R, Lindsey CJ, (2000). Brain kallikrein-kinin system: from receptors to neuronal pathways and physiological functions. In:, Quinton P, Björklund A, Hökfelt T, (eds). Handbook of Chemical Anatomy: Peptide Receptors. Elsevier: Amsterdam, pp. 241-298.
16. Dolber PC, Gu B, Zhang X, Fraser MO, Thor KB, Reiter JP, (2007). Activation of the external urethral sphincter central pattern generator by a 5-HT(1A) receptor agonist in rats with chronic spinal cord injury. Am J Physiol Regul Integr Comp Physiol 292: R1699-R1706.
17. El Sayah M, Medeiros R, Fernandes ES, Campos MM, Calixto JB, (2006). Mechanisms underlying up-regulation in the pig Iris sphincter in vitro. Mol Pharmacol 69: 1701-1708.
18. Félétou M, Germain M, Thurieau C, Fauchere JL, Canat E, (1994). Agonistic and antagonist properties of the bradykinin B2 receptor antagonist, HOE-140, in isolated blood vessels from different species. Br J Pharmacol 112: 683-689.
19. Fernandes ES, Passos GF, Campos MM, de Souza GEP, Fittipaldi JF, Pesquero JL, et al,. (2005). Cytokines and neutrophils as important mediators of platelet-activating factor-induced kinin B1 receptor expression. Br J Pharmacol 146: 209-216.
20. Ferreira J, Beirith A, Mori MA, Araújo RC, Bader M, Pesquero JB, et al,. (2005). Reduced nerve injury-induced neuropathic pain in kinin B1 receptor knock-out mice. J Neurosci 25: 2405-2412.
21. Fox A, Kaur S, Li B, Panesar M, Saha U, Davis C, et al,. (2005). Antihyperalgesic activity of a novel nonpeptide bradykinin B1 receptor antagonist in transgenic mice expressing the human B1 receptor. Br J Pharmacol 144: 889-899.
22. Giuliani S, Santicioli P, Lippe IT, Lecci A, Maggi CA, (1993). Effect of bradykinin and tachykinin receptor antagonist on xylene-induced cystitis in rats. J Urol 150: 1014-1017.
23. 1 receptor: biochemical and pharmacological characterization. J Pharmacol Exp Ther 309: 661-669.
24. de Groat WC, (1990). Central neural control of the lower urinary tract. Ciba Found Symp 151: 27-44.
25. de Groat WC, Booth AM, Yoshimura N, (1993). Neurophysiology of micturition and its modification in animal models of human disease. In:, Maggi CA, (ed.). Nervous Control of Urogenital System. Harwood Academic: London, pp. 227-290.
26. Gulur DM, Drake MJ, (2010). Management of overactive urinary bladder. Nat. Rev Urol 7: 572-582.
27. Hall JM, Morton IKM, (1997). The pharmacology and immunopharmacology of kinin receptors. In:, Farmer SG, (ed.). The Kinin System. Academic Press: London, pp. 9-43.
28. Hara DB, Leite DF, Fernandes ES, Passos GF, Guimarães AO, Pesquero JB, et al,. (2008). The relevance of kinin B1 receptor upregulation in a mouse model of colitis. Br J Pharmacol 154: 1276-1286.
29. Hock FJ, Wirth K, Albus U, Linz W, Gerhards HJ, Wiemer G, et al,. (1991). Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol 102: 769-773.
30. Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P, (2011). Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 108: 1132-1138.
31. Juszczak K, Ziomber A, Wyczolkowski M, Thor PJ, (2009). Urodynamic effects of the bladder C-fiber afferent activity modulation in chronic model of overactive bladder in rats. J Physiol Pharmacol 60: 85-91.
32. Kajekar R, Myers AC, (2000). Effect of bradykinin on membrane properties of guinea pig bronchial parasympathetic ganglion neurones. Am J Physiol Lung Cell Mol Physiol 278: L485-L491.
33. Kayashima Y, Smithies O, Kakoki M, (2011). The kallikrein-kinin system and oxidative stress. Curr Opin Nephrol Hypertens 21: 92-96.
34. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
35. Kruse MN, LA B, de Groat WC, (1995). Influence of spinal cord injury on the morphology of urinary bladder afferent and efferent neurons. J Auton Nerv Syst 54: 215-224.
36. Lecci A, Maggi CA, (2005). Overactive urinary bladder: targeting sensory pathways. Drug Discov Today 2: 15-23.
37. Lecci A, Giuliani S, Meini S, Maggi CA, (1995). Pharmacological analysis of the local and reflex responses to bradykinin on rat urinary bladder motility in vivo. Br J Pharmacol 114: 708-714.
38. Lecci A, Meini S, Tramontana M, Giuliani S, Criscuoli M, Maggi CA, (1999). Capsaicin pretreatment does not alter rat urinary bladder motor responses induced by a kinin B1 receptor agonist after endotoxin treatment. Neurosci Lett 262: 73-76.
39. Lee CH, Shieh DC, Tzeng CY, Chen CP, Want SP, Chiu CY, et al,. (2008). Bradykinin-induced IL-6 expression through bradykinin B2 receptor, phospholipase C, protein kinase Cdelta and NF-kB pathway in human synovial fibroblasts. Mol Immunol 45: 3693-3702.
40. Lee JY, Kim BJ, Sim G, Kim GT, Kang D, Jung JH, et al,. (2011). Spinal cord injury markedly altered protein expression patterns in the affected rat urinary bladder during healing stages. J Korean Med Sci 26: 814-823.
41. Leeb-Lundberg LM, Marceau F, Müller-Esterl W, Pettibone DJ, Zuraw BL, (2005). International Union of Pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 57: 27-77.
42. Lembeck F, Griesbacher T, Eckhardt M, Henke S, Breipohl G, Knolle J, (1991). New, long-acting, potent bradykinin antagonists. Br J Pharmacol 102: 297-304.
43. Levy D, Zochodne D, (2000). Increased mRNA expression of B1 and B2 bradykinin receptors and antinociceptive effects of their antagonists in an animal model of neuropathic pain. Pain 86: 265-271.
44. Limberg BJ, Andersson KE, Aura Kullmann F, Burmer G, de Groat WC, Rosenbaum JS, (2010). β-Adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female urinary bladder. Cell Tissue Res 342: 295-306.
45. Liu SP, Volfson I, Levin RM, (1998). Effects of hypoxia, calcium, carbachol, atropine and tetrodotoxin on the filling of the in-vitro rabbit whole bladder. J Urol 160: 913-919.
46. Ma QP, Heavens R, (2001). Basal expression of bradykinin B(1) receptor in the spinal cord in humans and rats. Neuroreport 12: 2311-2314.
47. Ma QP, Hill R, Sirinathsinghji D, (2000). Basal expression of bradykinin B1 receptor in peripheral sensory ganglia in the rat. Neuroreport 11: 4003-4005.
48. Maggi CA, (1997). Bradykinin as an inflammatory mediator in the urinary tract. In:, Farmer SG, (ed.). The Kinin System. Academic Press: London, pp. 235-247a.
49. Marceau F, Barabé J, St-Pierre S, Regoli D, (1980). Kinin receptors in experimental inflammation. Can J Physiol Pharmacol 58: 536-542.
50. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
51. Meini S, Patacchini R, Giuliani S, Lazzeri M, Turini D, Maggi CA, et al,. (2000). Characterization of bradykinin B2 receptor antagonists in human and rat urinary bladder. Eur J Pharmacol 2: 177-182.
52. Moreau ME, Garbacki N, Molinar G, Brown NJ, Marceau F, Adam A, (2005). The Kallikrein-Kinin system: current and future pharmacological targets. J Pharmacol Sci 99: 6-38.
53. Ni A, Yin H, Agata J, Yang Z, Chao L, Chao J, (2003). Overexpression of kinin B1 receptors induces hypertensive response to des-Arg9-bradykinin and susceptibility to inflammation. J Biol Chem 278: 219-225.
54. Passos GF, Fernandes ES, Campos MM, Araujo JGVC, Pesquero JL, Souza GEP, et al,. (2004). Kinin B1 receptor upregulation after lipopolysaccharide administration: role of proinflammatory cytokines and neutrophil influx. J Immunol 172: 1839-1847.
55. Patra PB, Westfall DP, (1996). Potentiation by bradykinin and substance P of purinergic neurotransmission in urinary bladder. J Urol 156: 532-535.
56. Phagoo SB, Poole S, Leeb-Lundberg LMF, (1999). Autoregulation of bradykinin receptors: agonists in the presence of interleukin-1beta shift the repertoire of receptor subtypes from B2 to B1 in human lung fibroblasts. Mol Pharmacol 56: 325-333.
57. Rashid MH, Inoue M, Matsumoto M, Ueda H, (2004). Switching of bradykinin-mediated nociception following partial sciatic nerve injury in mice. J Pharmacol Exp Ther 308: 1158-1164.
58. Regoli D, Allogho SN, Rizzi A, Gobeil FJ, (1998). Bradykinin receptors and their antagonists. Eur J Pharmacol 348: 1-10.
59. Rhaleb NE, Rouissi N, Jukic D, Regoli D, Henke S, Breipohl G, et al,. (1992). Pharmacological characterization of a new highly potent B2 receptor antagonist (Hoe 140: D-Arg-[Hyp3,Thi5,D-Tic7,Qic8]bradykinin). Eur J Pharmacol 210: 115-120.
60. Santos-Benito FF, Muñoz-Quiles C, Ramõn-Cueto A, (2006). Long-term care of paraplegic laboratory mammals. J Neurotrauma 23: 521-536.
61. 1-receptor in cultured human lung fibroblasts. J Clin Invest 101: 2080-2091.
62. Shughrue PJ, Ky B, Austin CP, (2003). Localization of B1 bradykinin receptor mRNA in the primate brain and spinal cord: an in situ hybridization study. J Comp Neurol 465: 372-384.
63. Sjuve R, Boels PJ, Uvelius B, Arner A, (2000). Up-regulation of bradykinin response in rat and human urinary bladder smooth muscle. J Urol 164: 1757-1763.
64. Smith AL, Wein AJ, (2010). Recent advances in management of urinary bladder overactivity. Med Rep 2: 1-7.
65. 2 receptor more effectively reduces postischemic blood-brain barrier disruption and cytokines release than B1 receptor inhibition. Biochem Biophys Res Commun 16: 205-211.
66. Takahara Y, Maeda M, Nakatani T, Kiyama H, (2007). Transient suppression of the vesicular acetylcholine transporter in urinary bladder pathways following spinal cord injury. Brain Res 1137: 20-28.
67. Thuret S, Moon LDF, Gage FH, (2006). Therapeutic interventions after spinal cord injury. Nat Rev Neurosci 7: 628-643.
68. Vanickà I, Urdzíková L, Saganová K, Cízková D, Gálik J, (2001). A simple and reproducible model of spinal cord injury induced by epidural balloon inflation in the rat. J Neurotrauma 18: 1399-1407.
69. Wirth K, Hock FJ, Albus U, Linz W, Alpermann HG, Anagnostopoulos H, et al,. (1991). Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol 3: 774-777.
70. Wotherspoon G, Winter J, (2000). Bradykinin B1 receptor is constitutively expressed in the rat sensory nervous system. Neurosci Lett 294: 175-178.
71. Yoshimura N, Chancellor M, (2003). Neurophysiology of lower urinary tract function and dysfunction. Rev Urol 5: S3-S10.
72. Yoshimura N, de Groat WC, (1997). Neural control of the lower urinary tract. Int J Urol 4: 111-125.